<HTML>
<HEAD><TITLE>CHOLERA VACCINE</TITLE></HEAD>
<BODY BGCOLOR=FFFFFF TEXT=000000 LINK=800000 VLINK=800000 ALINK=800000>
<A HREF=/pharm><IMG SRC=/pharm/tbarend.gif ALIGN=RIGHT HSPACE=0 HEIGHT=30 WIDTH=172 BORDER=0></A>
<IMG SRC=/pharm/tbar.gif ALIGN=LEFT HEIGHT=30 WIDTH=100%>
<BR CLEAR=ALL>
<CENTER>
<FONT SIZE=2>
<B><A HREF=#INDICATIONS>INDICATIONS</A></B>&nbsp;&nbsp;&nbsp;&nbsp;
<B><A HREF=#CONTRA-INDICATIONS>CONTRA-INDICATIONS</A></B>&nbsp;&nbsp;&nbsp;&nbsp;
<B><A HREF=#DOSAGE>DOSAGE</A></B>&nbsp;&nbsp;&nbsp;&nbsp;
<B><A HREF=#SIDE-EFFECTS>SIDE-EFFECTS</A></B>&nbsp;&nbsp;&nbsp;&nbsp;
PREGNANCY&nbsp;&nbsp;&nbsp;&nbsp;
<B><A HREF=#OVERDOSE>OVERDOSE</A></B>&nbsp;&nbsp;&nbsp;&nbsp;
<B><A HREF=#IDENTIFICATION>IDENTIFICATION</A></B>&nbsp;&nbsp;&nbsp;&nbsp;
PATIENT&nbsp;INFORMATION
</FONT>
</CENTER>
<IMG SRC=/pharm/thinbar.gif ALIGN=LEFT HEIGHT=10 WIDTH=100%>
<BR CLEAR=ALL>
<IMG ALT=Logo SRC=logo.gif ALIGN=RIGHT BORDER=0><FONT SIZE=5><B>
CHOLERA VACCINE<BR>

</B></FONT>
<BR>
<FONT SIZE=2><B>CHOLERA VACCINE<BR>
</B>Cho/Vac<BR>
<B>PROPRIETARY NAME:<BR>
</B></FONT><FONT SIZE=3><B>CHOLERA VACCINE<BR><BR>
</B></FONT><FONT SIZE=2><B>DESCRIPTIVE NAME:<BR>
</B>A Bacterial Cholera Prophylactic Vaccine<BR><BR>
<B>REGISTRATION NUMBER:<BR>
</B>T537 (Act 101/1965)<BR><BR>
<B>PHARMACOLOGICAL CLASSIFICATION:<BR>
</B>A30.1 Antigens<BR><BR>
<B>SCHEDULING STATUS:<BR>
</B>S2<BR><><FONT SIZE=2><B>DESCRIPTIVE NAME:<BR>
</B>A Bacterial Cholera Prophylactic Vaccine<BR><BR>
<B>REGISTRATION NUMBER:<BR>
</B>T537 (Act 101/1965)<BR><BRBR>
<B>COMPOSITION:<BR>
</B>A suspension in a phosphate buffered saline solution of equal parts of cholera vibrios of serotypes INABA and OGAWA to give 8000 million per 1 mL dose with 0,05% phenol as preservative.<BR><BR>
<B><A NAME=IDENTIFICATION></A>IDENTIFICATION:<BR>
</B>A pale milky translucent suspension with a slight odour due to the preservative.<BR><BR>
<B>PHARMACOLOGICAL ACTION:<BR>
</B>Induces in the recipient a specific immunity to cholera.<BR><BR>
<B><A NAME=INDICATIONS></A>INDICATIONS:<BR>
</B>For active immunisation against cholera.<BR><BR>
<B><A NAME=CONTRA-INDICATIONS></A>CONTRA-INDICATIONS:<BR>
</B>Not recommended for patients with an acute infections or for children less than one year old.  Should be used with great caution if there has been a history of allergy to previous vaccination.<BR><BR>
<B><A NAME=DOSAGE></A>DOSAGE AND DIRECTIONS FOR USE:<BR>
</B>For primary immunisation of adults or children of 14 years or older, two (2) doses of 1 mL are given by subcutaneous injection 14 days apart.  It may be expected to confer immunity in about 50% of subjects for up to six months, but persons at risk should be aware of the importance of good hygiene and safe drinking water in the prevention of cholera.  The dose for children over 1 year old should be between 0,1 mL and 1 mL in proportion to body mass.  Further doses may be given at 6 monthly intervals if required.  Not recommended for children less than 1 year old.  Sterilise the rubber closure with tincture of iodine and shake vial vigorously before use.<BR><BR>
<B>N.B. The immunogenic activity of Cholera is reduced if given within three weeks of a yellow fever injection.<BR><BR>
<A NAME=SIDE-EFFECTS></A>SIDE EFFECTS AND SPECIAL PRECAUTIONS:<BR>
</B>Enquiry regarding previous hypersensitivity should precede the administration of a vaccine, and measures to treat reactions should be immediately available.  Anaphylactic reactions, which are rare, should be treated with adrenaline, possibly in association with antihistamine and corticosteroid therapy.<BR><BR>
Reactions following administration may include anorexia, fever, vomiting, and malaise.  May cause transient local and general reactions for which symptomatic treatment should be given.  Neurological or psychiatric reactions have occasionally occurred as have the occasional slight swelling, erythema and tenderness at the injection site.<BR><BR>
<B><A NAME=OVERDOSE></A>KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:<BR>
</B>No known symptoms<BR><BR>
<B>PRESENTATION:<BR>
</B>Multidose 10 mL vials (10 doses) packed singly.<BR>
Multidose 10 mL vials packed 10 x 10 mL.<BR><BR>
<B>STORAGE INSTRUCTIONS:<BR>
</B>Store at 2&#176; C to 10&#176; C.  DO NOT FREEZE.  Protect from light.<BR><BR>
<B>NAME AND BUSINESS ADDRESS OF APPLICANT:<BR>
</B>The South African Institute for Medical Research.<BR>
Rietfontein, Edenvale, Transvaal.<BR>
P.O. Box 28999, Sandringham, 2131<BR><BR>
<B>DATE OF PUBLICATION OF THIS PACKAGE INSERT:<BR>
</B>June 1990<BR><BR>
</FONT><FONT SIZE=1>102-1292</FONT><CENTER>
<FONT SIZE=2>
<B>
<IMG SRC=/pharm/thinbar.gif ALIGN=LEFT HEIGHT=10 WIDTH=100%>
<BR CLEAR=ALL>
<A HREF=/pharm>SAEPI HOME PAGE</A>
&nbsp;&nbsp;&nbsp;&nbsp;
<A HREF=/pharm/index/index_T_A.shtml>TRADE NAME INDEX</A>
&nbsp;&nbsp;&nbsp;&nbsp;
<A HREF=/pharm/index/index_G_A.shtml>GENERIC NAME INDEX</A>
&nbsp;&nbsp;&nbsp;&nbsp;
<A HREF=/pharm/feedback.html>FEEDBACK</A>
<IMG SRC=/pharm/thinbar.gif ALIGN=LEFT HEIGHT=10 WIDTH=100%>
<BR CLEAR=ALL>
</B>
</FONT>
</CENTER>
<CENTER><FONT SIZE=2>Information presented by Malahyde Information Systems &copy; Copyright 1996,1997,1998</FONT></CENTER>
</BODY>
</HTML>
tml>FEEDBACK</A>
<IMG SRC=/pharm/thinbar.gif ALIGN=LEFT HEIGHT=10 WIDTH=100%>
<BR CLEAR=ALL>
</B>
</FONT>
</CENTER>
<CENTER><FONT SIZE=2>Information presented